Human Xtensions: What Is Still Left in the Old Asset Sale, When the Final $200 Thousand Really Becomes Available, and Where the Indemnity Sits
The remaining $200 thousand looks like a receivable in the report, but it is still not available cash: the second closing must be completed first, the amount must be placed in escrow, and the company still has to make it through a chain of contractual conditions. For a company that ended 2025 with only NIS 991 thousand of cash and no real operating activity, that gap between accounting and liquidity is material.
What Is Actually Left From the Old Sale
The main article already established the core point: after selling its assets, Human Xtensions was left without a real operating business and without a comfortable cash cushion. This follow-up isolates the last $200 thousand of the sale because, in the report, it can look like a routine tail-end receivable. In practice, it sits at the intersection of the second closing, escrow, representations, covenants, and indemnity.
This is not cash on hand. Contractually, total consideration in the asset sale is $1 million plus VAT. Of that, $800 thousand was tied to the first two closing milestones, and after the amendment to the agreement those two payments were combined and paid at the first closing. The remaining $200 thousand is not supposed to go directly to the company at all. It first has to be deposited with an agreed Israeli trustee at the second closing, and only then can it be released to the company at the third closing.
The important gap is between three different layers of the same amount:
| Layer | What the report shows | Economic meaning |
|---|---|---|
| Contractual | $200 thousand is supposed to be deposited with the trustee at the second closing | Until the second closing is completed, the money has not even entered the escrow mechanism |
| Accounting | Note 12 shows NIS 622 thousand of deferred consideration inside the sale accounting | Accounting has already assigned value to the future payment before it is free cash |
| Balance sheet | The year-end balance sheet includes NIS 604 thousand as a sale receivable | This is a conditional contractual right, not cash sitting in the bank |
That distinction matters because this is not a normal operating company that can absorb timing noise more easily. This is a shell without real operating activity, so every few hundred thousand shekels matter not only by their accounting value but by whether they are actually available to fund the period until the next transaction.
When Does The $200 Thousand Really Become Available
The report describes a staged mechanism, not a single fixed payment date. The second-closing conditions mainly relate to transferring the intellectual property, licenses, and regulatory approvals to the buyer, including FDA and CE approvals. Only once that second stage is completed is the buyer supposed to place the $200 thousand with the trustee. That means that, as of the report date, there is still no amount sitting in escrow waiting to be released. There is only a contractual right to have such an amount deposited if and when the second closing is completed.
That is where a superficial reading of the balance sheet can go wrong. Accounting is already pulling the amount forward: Note 12 updates the fair value of the disposal group and, inside the sale calculation, shows NIS 2.707 million of cash received and NIS 622 thousand of deferred consideration. But the contractual note says explicitly that, as of the signing date of the financial statements, the company was still working to complete the second stage. In other words, the company recognized an asset based on a mechanism whose critical legal step had not yet happened.
The complexity does not stop there. The third closing is defined as 12 months from the first closing, but it is also subject to the company having complied with all agreements and covenants, the truth of its representations, and the fulfillment of its obligations throughout the period between the first and third closing. So even after the second closing is eventually completed, the amount does not automatically become free corporate cash. It still has to make it through a period of clean contractual performance.
That chart shows why the amount cannot be treated as a side note. At the end of 2025 the company had NIS 991 thousand of cash and cash equivalents, NIS 75 thousand of restricted deposits, and NIS 604 thousand of receivables from the sale. In other words, that receivable was equal to roughly 61% of year-end cash and nearly one-third of current assets. For a company with such a narrow asset base, the difference between a conditional receivable and accessible cash is no longer technical.
Where The Indemnity Actually Sits
This is the real friction point. The same $200 thousand the company is waiting for is also the buyer’s sole indemnity pool. Under the agreement, for 12 months after the second closing the company is required to indemnify the buyer for damages and losses during the indemnity period. The list includes inaccuracies or breaches of representations, undertakings, or covenants that could lead to a decline of more than $20 thousand in the value of the assets, third-party claims tied to the business or liabilities from before the second closing, and assets or liabilities that were not transferred under the agreement.
The key issue is not just that indemnity exists, but where it sits. The indemnity cap is limited to the amount deposited with the trustee, meaning up to $200 thousand, and the buyer may recover only from that escrowed portion of the consideration. That helps on one level because the exposure is ring-fenced and cannot spill beyond that amount. But it also means the last part of the sale proceeds is not simply “another $200 thousand” that joins the company’s cash balance. It first functions as the buyer’s protection layer against claims and breaches during the interim period.
Put differently, the final payment plays two roles at the same time: it is both the residual consideration the company wants to receive and the contractual security the buyer wants to keep. Until both roles are resolved, it is hard to treat the amount as capital that has already been accumulated.
Why This Matters Now
The economic importance of this mechanism does not come only from the legal drafting. It comes from the company’s condition. At the end of 2025 it had NIS 991 thousand of cash, while the cash flow statement shows NIS 5.901 million of cash used in operating activities during the year. The directors wrote that, if the asset sale were not completed and a public equity raise were not executed, the company’s cash balance was expected to fund operations only until May 2026. Note 1 is even sharper: the financing sources available at the approval date of the financial statements were not sufficient for 12 months, creating substantial doubt about the company’s ability to continue as a going concern.
That is the core continuation thesis. The residual sale proceeds are a material asset, but not material liquidity yet. The report already pulls them into the balance sheet as a receivable, but the path from balance-sheet recognition to usable cash still runs through two more gates: first, completion of the second stage and funding of escrow, and second, continued compliance with representations, covenants, and undertakings until the third closing, while the same amount also serves as the buyer’s indemnity backstop.
So when someone looks at the NIS 604 thousand sale receivable and treats it as almost cash, they are flattening precisely the distinction the filing itself is making. Legally and in liquidity terms, the amount is still ring-fenced. It is not a certain shortfall, but it is also not a resource the company can reasonably count as already released.
Bottom Line
If the story is reduced to one line, the final payment in the asset sale is a conditional right with built-in buyer protection, not cash waiting for a date.
That makes the amount more important than it looks on a first pass. It equals a meaningful portion of the company’s year-end cash, so even a modest gap between accounting recognition and actual availability changes the liquidity picture. At the same time, the fact that the indemnity cap is limited to that same amount and recoveries are limited to the escrow prevents the exposure from leaking beyond it. The real question is therefore not whether the company is “supposed” to receive the last $200 thousand, but when and whether that amount stops being conditional, contractually ring-fenced consideration and actually becomes free cash.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.